Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials

被引:0
作者
Hammadeh, Bara M. [1 ]
Younis, Osama M. [2 ]
Alsufi, Muaath I. [2 ]
Idrees, Muhammad [3 ]
Hussein, Ayham Mohammad [1 ]
Aldalati, Abdullah Yousef [4 ]
Qtaishat, Fares A. [2 ]
Qatawneh, Banan [1 ]
Bugazia, Al [5 ]
Hamed, Raed A. [6 ,7 ]
机构
[1] Al Balqa Applied Univ, Fac Med, Salt 11185, Jordan
[2] Univ Jordan, Fac Med, Amman, Jordan
[3] Lahore Gen Hosp, Fac Med, Lahore, Pakistan
[4] Jordan Univ Sci & Technol, Fac Med, Irbid, Jordan
[5] Univ Wisconsin, Dept Med, Madison, WI USA
[6] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA
[7] Aurora Sinai Med Ctr, Milwaukee, WI USA
关键词
COPD; ensifentrine; PDE4; TSA; OBSTRUCTIVE PULMONARY-DISEASE; 4 INHIBITOR ENSIFENTRINE; PHOSPHODIESTERASE INHIBITORS; ROFLUMILAST; IMPROVEMENT; TIOTROPIUM;
D O I
10.1177/17534666251347775
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Chronic obstructive pulmonary disease (COPD) is a progressive lung disease marked by airway inflammation and obstruction. Ensifentrine is a novel inhaled PDE3 and PDE4 inhibitor with both bronchodilator and anti-inflammatory effects.Objectives: Comprehensively review the available evidence on ensifentrine and its potential role in COPD management.Design: Systematic review and meta-analysis with trial sequential analysis of randomized clinical trials.Data sources and methods: We systematically searched PubMed, Scopus, ScienceDirect, Cochrane Library, and Medline for clinical trials published between 2018 and August 2024 that evaluated the safety and efficacy of ensifentrine in patients with COPD. We assessed study quality using the RoB 2 tool and conducted the meta-analysis with the "meta" package in R (version 4.3.2), using the mean difference with a 95% confidence interval to evaluate changes in outcomes.Results: Five studies met the predefined inclusion criteria with 2519 participants. At week 12, the pooled analysis indicated that forced expiratory volume in 1 s (FEV1) and trough FEV1 were significantly increased in the ensifentrine group (mean difference (MD): 91.32; 95% CI: 69.63 to 113.01) and (MD: 40.90; 95% CI: 19.65 to 62.15), respectively. At week 24, the pooled analysis indicated that the evaluating respiratory symptoms total score was significantly decreased in the ensifentrine group (MD: -0.81; 95% CI: -1.36 to -0.27), transition dyspnea index score was significantly increased in the ensifentrine group (MD: 0.96; 95% CI: 0.62 to 1.29), no significant difference was observed in rescue medication use (MD: -0.30; 95% CI: -0.60 to 0.00), and no significant difference was observed in St. George's Respiratory Questionnaire total score (MD: -1.46; 95% CI: -3.22 to 0.30). Based on subgroup analysis, higher doses were associated with more favorable results.Conclusion: In conclusion, owing to its dual effects, ensifentrine has a significant impact on improving pulmonary function and quality of life with minimal side effects. Promising results are expected if implied by synergizing with other drugs, however, more studies are needed to study the long-term effect on disease progression.Trial registration: The study protocol was published via PROSPERO: International Prospective Register of Systematic Reviews (#CRD42024570799).
引用
收藏
页数:17
相关论文
共 49 条
[1]   Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials) [J].
Anzueto, Antonio ;
Barjaktarevic, Igor Z. ;
Siler, Thomas M. ;
Rheault, Tara ;
Bengtsson, Thomas ;
Rickard, Kathleen ;
Sciurba, Frank .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (04) :406-416
[2]   How to perform a meta-analysis with R: a practical tutorial [J].
Balduzzi, Sara ;
Ruecker, Gerta ;
Schwarzer, Guido .
EVIDENCE-BASED MENTAL HEALTH, 2019, 22 (04) :153-160
[3]   Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease [J].
Banner, Katharine H. ;
Press, Neil J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (06) :892-906
[4]   Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma [J].
Bjermer, Leif ;
Abbott-Banner, Katharine ;
Newman, Kenneth .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 58
[5]  
Brown BD., 2025, StatPearls
[6]   Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials [J].
Calverley, Peter M. A. ;
Rabe, Klaus F. ;
Goehring, Udo-Michael ;
Kristiansen, Soren ;
Fabbri, Leonardo M. ;
Martinez, Fernando J. .
LANCET, 2009, 374 (9691) :685-694
[7]   Pharmacological Interpretation of the Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease: Insights from ENHANCE Trials [J].
Calzetta, Luigino ;
Cazzola, Mario ;
Rogliani, Paola .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (02) :224-225
[8]   Short-Term Impact of the Frequency of COPD Exacerbations on Quality of Life [J].
Camac, Erin R. ;
Stumpf, Natalie A. ;
Voelker, Helen K. ;
Criner, Gerard J. .
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2022, 9 (03) :298-308
[9]   Novel Anti-Inflammatory Approaches to COPD [J].
Cazzola, Mario ;
Hanania, Nicola A. ;
Page, Clive P. ;
Matera, Maria Gabriella .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 :1333-1352
[10]   Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions [J].
Cumpston, Miranda ;
Li, Tianjing ;
Page, Matthew J. ;
Chandler, Jacqueline ;
Welch, Vivian A. ;
Higgins, Julian P. T. ;
Thomas, James .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10)